TAR

DeepGlint Igniting AI Aspirations amongst Malaysian New Generation

Retrieved on: 
Monday, March 25, 2024
Faculty, Computing, BHD, Environment, Assistant, Initiative, Shanghai Stock Exchange, Education, Information technology, Management, TAR, Student

DeepGlint, a frontrunner in AI, computer vision, and big data analysis, showcased the Group's innovative solutions across various domains, including the metaverse, intelligent sports, and traffic management.

Key Points: 
  • DeepGlint, a frontrunner in AI, computer vision, and big data analysis, showcased the Group's innovative solutions across various domains, including the metaverse, intelligent sports, and traffic management.
  • The event marked a significant step towards strengthening Malaysia's foothold in the global AI landscape, aligning with Malaysia's vision for greater talent exchange with China.
  • In a pivotal move, DeepGlint also announced the cooperation with a Malaysian AI company, DeepCore Sdn.
  • Mr. Zhao Yong, Founder and Chief Executive Officer of DeepGlint said, "We are pleased to see so many talents in Malaysia.

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, PMN, MSA, Bioorganic chemistry, ALS, Multiple system atrophy, Zebrafish, SOD1, Neuroscience, Journal, Brain cell, TAR, Protein, Biochemistry, PROMIS, Antibody, Therapy, Vaccine

ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.

Key Points: 
  • ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.
  • ALS is a fatal neurodegenerative disease of motor neurons.
  • “Publication of these data underscores the connection of misfolded proteins and ALS and supports targeting our TDP-43-specific epitope with PMN267 as a potential therapeutic approach,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • “PMN267 is advancing through preclinical development and is showing promise as a potential treatment for ALS.

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 2, 2024
Research, Failure, Plasma, KPMG, TDP43, Disease, PD, CSF, Yale University, Patient, Inflammation, Biomarker, CMC, Equity, TAR, Human, European, Drug development, ATM, Safety, Phase, Therapy, Vaccine, Treasury, Syneos Health, Axonal transport, Pharmaceutical industry

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.

Key Points: 
  • MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.
  • For the quarter ended December 31, 2023, Annovis reported a net loss of $22.2 million, compared to a net loss of $7.7 million for the same period in 2022.
  • For the full year ended 2023, Annovis reported a net loss of $56.2 million, compared to a net loss of $25.3 million in 2022.
  • Other income (expense) for the quarter ended December 31, 2023 was ($11.2) million, compared to $0.2 million for the same period in 2022.

Lexbe Unveils AutoPilot: Revolutionary GenAI-Powered Automated Document Review

Retrieved on: 
Tuesday, March 19, 2024
Automation, Synthetic media, Entrepreneurship, PHI, Risk, Autopilot, Warner Bros. Discovery EMEA, Research, PII, ESI, TAR, Human, CAL, Generative, Medical device

AUSTIN, Texas, March 19, 2024 (GLOBE NEWSWIRE) -- Lexbe , a leading provider of generative artificial intelligence (GenAI) powered eDiscovery solutions, is proud to announce the launch of Lexbe AutoPilot , an innovative GenAI-powered automated document review solution designed to revolutionize the document review process for responsiveness, privilege, and other key legal classification and summarization.

Key Points: 
  • AUSTIN, Texas, March 19, 2024 (GLOBE NEWSWIRE) -- Lexbe , a leading provider of generative artificial intelligence (GenAI) powered eDiscovery solutions, is proud to announce the launch of Lexbe AutoPilot , an innovative GenAI-powered automated document review solution designed to revolutionize the document review process for responsiveness, privilege, and other key legal classification and summarization.
  • Lexbe AutoPilot can be used as an effective ‘first pass review’ to make a matter ready for review by human reviewers within law firms or in contract managed review firms.
  • Also, Lexbe AutoPilot can be combined with state-of-the-art statistical sampling to classify and produce responsive documents with manual human review limited to quality control.
  • AutoPilot harnesses the power of Generative AI to transform how legal professionals handle document review.

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, March 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

AI in eDiscovery: How to Balance Opportunity with Caution

Retrieved on: 
Tuesday, March 5, 2024
Bias, Algorithm, TAR, AI, Azure, MSP, Microsoft Azure, Risk, Synthetic media, Warner Bros. Discovery EMEA, E-governance, Privacy, PII, Microsoft, Medical device

HOBOKEN, N.J., March 5, 2024 /PRNewswire-PRWeb/ -- eMazzanti Technologies, a NYC area legal technology expert and MSP describes how AI continues to revolutionize eDiscovery in a new article. The author shares how the introduction of technology-assisted review (TAR) several years ago proved pivotal, delivering savings in time and cost.

Key Points: 
  • Exploding data volumes force legal professionals to walk a tightrope between identifying all relevant information and managing cost and risk.
  • AI solves many problems and has become indispensable, but legal teams should proceed carefully.
  • Below are a few excerpts from the article, " AI in eDiscovery: Balancing Opportunity with Caution ."
  • Legal teams should critically evaluate AI solutions, ensure human oversight, and address ethical considerations throughout the process.

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia

Retrieved on: 
Monday, March 4, 2024
Alzheimer's disease, ALS, Real-time, TAR, Synapse, Pathology, Neuron, Neurodegenerative disease, Asos, SNARE, Conference, Frontotemporal dementia, FTD, IPSC, RNA, Phenotype, Patient, Spinal cord, Brain cell, DSM-IV codes, Brain

CAMBRIDGE, Mass., March 4, 2024 /PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that will alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, today announced preclinical data that showed the company's UNC13A splice-switching antisense oligonucleotides (ASOs) modulate UNC13A splicing and restore normal synaptic activities in ALS and FTD. QurAlis' ASOs prevented cryptic exon inclusion in UNC13A transcripts, increased UNC13A protein levels, and normalized localization of UNC13A protein at the synapse.

Key Points: 
  • QurAlis' ASOs prevented cryptic exon inclusion in UNC13A transcripts, increased UNC13A protein levels, and normalized localization of UNC13A protein at the synapse.
  • A defining feature of both sporadic and familial disease is the cytoplasmic mis-localization of TAR DNA Binding Protein-43 (TDP-43).
  • "QurAlis has identified ASOs that modulate UNC13A splicing and restore normal synaptic activities.
  • QurAlis' ASOs restored all or some aspects of SNARE complex assembly and synaptic vesicle fusion and release.

The Rainwater Charitable Foundation Announces 2024 Rainwater Prize Winners, Dr. Virginia Man-Yee Lee and Dr. Cristian Lasagna-Reeves, for Ongoing Contributions to Scientific Understanding of Tau in the Brain

Retrieved on: 
Thursday, February 15, 2024
Yee, DNA-binding protein, Tauopathy, BSN, ALS, Research, Dementia, TAR, Nature Neuroscience, PSP, Rain, Pathology, Alpha-synuclein, Neurodegenerative disease, Conference, Frontotemporal dementia, University, Medical laboratory, Drug discovery, Innovation, Associate, Movement, Biology, Brain, Pharmaceutical industry

FORT WORTH, Texas, Feb. 15, 2024 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative research that enables field-advancing programs, resources and breakthrough solutions for primary tauopathies, today announced Virginia Man-Yee Lee, Ph.D., University of Pennsylvania Perelman School of Medicine, will be awarded the 2024 Outstanding Innovation in Neurodegenerative Disease Research Prize of $400,000, and Cristian Lasagna-Reeves, Ph.D., M.S., Indiana University School of Medicine will be awarded the Rainwater Prize for Innovative Early-Career Scientist of $200,000. The prizes will be presented during the Tau2024 Global Conference on March 25-26, 2024, in Washington, D.C.

Key Points: 
  • The Rainwater Prize Program , now in its fifth year, aims to highlight and support scientific progress toward addressing critical gaps for neurodegenerative diseases associated with the accumulation of the tau protein in the brain.
  • Currently, Dr. Lasagna-Reeves' lab focuses on understanding the role of tau in Alzheimer's disease and related dementias.
  • Dr. Lasagna-Reeves winning this year's Early-Career Prize recognizes the scientific discoveries that could lead to a potential new therapeutic approach for tauopathies.
  • We're proud to support their research and provide resources that may contribute to potential future breakthroughs in our understanding of tau."

Integration of AIDA Discovery Assistant with Relativity App Hub Marks a New Era in Legal Discovery

Retrieved on: 
Monday, January 29, 2024
Warner Bros. Discovery EMEA, Reference model, Administration, AIDA, TAR, LAER, EDRM, Medical device

NEW YORK, Jan. 29, 2024 /PRNewswire/ -- In a move that signifies a significant advancement in legal technology, LAER AI announces the integration of its groundbreaking product, AIDA Discovery Assistant, with the Relativity App Hub. This integration represents a transformative step forward, offering the expansive global Relativity community sophisticated AI tools that streamline legal discovery and document review processes.

Key Points: 
  • LAER AI's AIDA Discovery Assistant, now seamlessly integrated into the Relativity App Hub, brings an advanced AI-driven approach to legal discovery, redefining efficiency and precision for legal professionals.
  • NEW YORK, Jan. 29, 2024 /PRNewswire/ -- In a move that signifies a significant advancement in legal technology, LAER AI announces the integration of its groundbreaking product, AIDA Discovery Assistant, with the Relativity App Hub.
  • This integration represents a transformative step forward, offering the expansive global Relativity community sophisticated AI tools that streamline legal discovery and document review processes.
  • AIDA Discovery Assistant's integration into the Relativity App Hub brings a host of benefits to legal professionals.

Lexbe Unveils Revolutionary CoPilot: A Groundbreaking AI Integration with GenAI Models, Like ChatGPT, Delivering Intelligent eDiscovery Automation

Retrieved on: 
Monday, January 22, 2024
Professional Services, Data Management, Technology, Legal, Other Technology, Software, Artificial Intelligence, Research, Multimedia, Warner Bros. Discovery EMEA, Lawyer, API, CAL, AI, Workflow, PII, White, TAR, Automation, Inc.

Lexbe Inc. , a leading eDiscovery provider, is thrilled to announce the launch of Lexbe CoPilot, a pioneering integration between the Lexbe eDiscovery Platform and generative AI large language models like ChatGPTSM and ClaudeSM.

Key Points: 
  • Lexbe Inc. , a leading eDiscovery provider, is thrilled to announce the launch of Lexbe CoPilot, a pioneering integration between the Lexbe eDiscovery Platform and generative AI large language models like ChatGPTSM and ClaudeSM.
  • This innovative solution is set to redefine how lawyers and other legal professionals navigate the complexities of eDiscovery.
  • "The ability of Lexbe CoPilot to process and analyze large volumes of data with nuanced understanding is revolutionary.
  • In addition to automating document review, Lexbe CoPilot automates many eDiscovery tasks, including: